Managing comorbidities in patients at the end of life

British Medical Journal

Volumn 329, Issue 7471, 2004, Pages 909-912

  Stevenson, James ^a   Abernethy, Amy P ^b   Miller, Cathy ^a   Currow, David C ^c  

^a REPATRIATION GENERAL HOSPITAL   (Australia)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HYPOCHOLESTEROLEMIC AGENT;

COMORBIDITY; DEATH; DRUG METABOLISM; HUMAN; HYPERTENSION; MEDICAL DECISION MAKING; PHYSICIAN; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; REVIEW; TACHYCARDIA; TERMINAL DISEASE; CHRONIC DISEASE; DECISION MAKING; METHODOLOGY; PATIENT ABANDONMENT; POLYPHARMACY; PROGNOSIS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; TERMINAL CARE; TERMINALLY ILL PATIENT;

CHRONIC DISEASE; COMORBIDITY; DECISION MAKING; HUMANS; POLYPHARMACY; PROGNOSIS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; REFUSAL TO TREAT; TERMINAL CARE; TERMINALLY ILL;

EID: 5144229478     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.329.7471.909     Document Type: Review

References (20)

1. Coebergh JW, Janssen-Heijnen ML, Post PN, Razenberg PP. Serious comorbidity among unselected cancer patients newly diagnosed in southeastern part of the Netherlands in 1993-1996. J Clin Epidemiol 1999;52:1131-6.
2. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States. JAMA 2002;287:337-44.
3. Goldberg RM, Mabee J, Chan L, Wong S. Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med 1996;14:447-50.
4. Mannesse CK, Derkx FHM, De Ridder MAJ, Man in't Veld AJ, Van der Cammen TJM. Contribution of adverse drug reactions to hospital admission of older patients. Age Ageing 2000;29:35-9.
5. Colven R, Harrington RD, Spach DH, Cohen CJ, Hooton TM. Retroviral rebound syndrome after cessation of suppressive antiretroviral therapy in three patients with chronic HIV infection. Ann Intern Med 2000;133:430-4.
6. Kotler DP. Cachexia. Ann Intern Med 2000;133:622-34.
7. Whelton PK, Appel LJ, Espeland MA, Applegate WB, Ettinger WH Jr, Kostis JB, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomised controlled trial of nonpharmacological interventions in the elderly (TONE). JAMA 1998;279:839-46.
8. Glare P, Virik K, Jones M, Hidson M, Eychmuller S, Simes J, et al. A systematic review of physicians' survival predictions in terminally ill cancer patients. BMJ 2003;327:195.
9. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment N Eng J Med 1988;318: 1728-33.
10. Hensrud DD. Clinical preventive medicine in primary care: background and practice: 1. Rationale and current preventive practices. Mayo Clin Proc 2000;75:165-72.
11. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
12. Diabetes Control and Complications Trial Research Group. Adverse events and their association with treatment regimens in the diabetes control and complications trial. Diabetes Care 1995;18:1415-27.
13. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
14. Guidelines Subcommittee. World Health Organisation-International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999;17:151-83.
15. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000;355:1955-64.
16. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
17. Progress Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41.
18. Olsen H, Klemstrud T, Stokke HP, Tretli S, Westheim A. Adverse drug reactions in current antihypertensive therapy: a general practice survey of 2586 patients in Norway. Blood Press 1999;8:94-101.
19. Ward SE, Viergutz G, Tormey D, de Muth J, Paulen A. Patient's reactions to completion of adjuvant breast cancer therapy. Nursing Research 1992;41:362-6.
20. Arnold EM. The cessation of cancer treatment as a crisis. Sec Work Health Care 1999;29:21-38.